Assessment of Serum Magnesium Level with Diabetic Foot Ulceration in Type II Diabetes Associated with Diabetic Nephropathy Patients
1 other identifier
observational
147
0 countries
N/A
Brief Summary
Magnesium (Mg), is the fourth most common cation in the body, with an essential role in fundamental biological reactions, whose deficiency provokes biochemical and symptomatic alterations in the human organism. This ion is now established as a central electrolyte in a large number of cellular metabolic reactions, including DNA and protein synthesis, neurotransmission, and hormone receptor binding. It is a component of GTPase and a cofactor for Na+/ K +-ATPase, adenylate cyclase, and phosphofructokinase. Magnesium is a cofactor in more than 300 cellular enzymatic systems and has a key role in cellular metabolism; the recognition that Mg deficiency or excess may be associated with significant clinical consequences has resulted in an increased interest in the utility of serum Mg measurement. Diabetes mellitus (DM), characterized by metabolic disorders related to high levels of serum glucose, is probably the most associated disease to Mg depletion in intra and extra cellular compartments. In several studies reduced magnesium concentrations have been observed in diabetic adults. Hypomagnesemia has been related as a cause of insulin resistance, also being a consequence of hyperglycemia, and when it is chronic leads to the installation of macro and microvascular complications of diabetes, worsening the deficiency of Mg. The association between diabetes mellitus and hypomagnesaemia is compelling for its wide ranging impact on diabetic control and complications. Hypomagnesaemia has been linked to poor glycemic control, coronary artery diseases, hypertension, foot ulceration and diabetic neuropathy . Nerve Conduction Test (NCS)is the gold standard test that should be performed to confirm the presence of neuropathy to determine it's severity and to differentiate other causes of neuropathy from diabetic neuropathy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2025
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 24, 2024
CompletedFirst Posted
Study publicly available on registry
January 1, 2025
CompletedStudy Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2026
CompletedJanuary 1, 2025
December 1, 2024
1 year
December 24, 2024
December 24, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Serum Magnesium level
Assessment Of Serum Magnesium level in type II diabetes patients
baseline
Study Arms (3)
group A
patients diagnosed as diabetic type 2 without complications
group B
patients diagnosed as diabetic type 2 with complications,it was 1.91±0.12
group C
Healthy control group
Eligibility Criteria
Diabetic type 2 Patients with complication as Diabetic foot ulceration Diabetic nephropathy CKD patients not on dialysis
You may qualify if:
- age\>18 years\<60 years Diabetic type 2 Patients with Diabetic foot ulceration Diabetic nephropathy CKD patients not on dialysis
You may not qualify if:
- Patients with recent infectious disease, immunological disorders, taking diuretics and magnesium containing antacids
- malabsorption syndrome, chronic diarrhea
- CKD Stage V on dialysis, pancreatitis, alcoholism, liver diseases
- tuberculosis, thyrotoxicosis, any malignancy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- resident doctor at Assiut University hospital
Study Record Dates
First Submitted
December 24, 2024
First Posted
January 1, 2025
Study Start
January 1, 2025
Primary Completion
January 1, 2026
Study Completion
March 1, 2026
Last Updated
January 1, 2025
Record last verified: 2024-12